Condition: HER2/Neu+ Uterine Serous Carcinoma · Sponsor: Yale University
Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective response rate and durable disease control rate. To assess overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma patients.
This description comes directly from the study's public registry record.
Alessandro D. Santin, M.D. · 203-737-4450 · alessandro.santin@yale.edu
Lisa Baker, R.N. · 203-785-6398 · lisa.baker@yale.edu
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center | Tucson, Arizona, United States | Completed |
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02491099